

DAFTAR PUSTAKA

- Ambler, R. P. 1980. The structure of b-lactamases. *Philos. Trans. R. Soc. Lond. (Biol.)* 289:321–331.
- Ariffin, H., P. Navaratnam, M. Mohamed, A. Arasu, W. A. Abdullah, C. L. Lee, dan L. H. Peng. 2000. Ceftazidime-resistant *Klebsiella pneumoniae* bloodstream infection in children with febrile neutropenia. *Int. J. Infect. Dis.* 4:21–25.
- Asensio, A., A. Oliver, P. Gonzalez-Diego, F. Baquero, J. C. Perez-Diaz, P. Ros, J. Cobo, M. Palacios, D. Lasheras, dan R. Canton. 2000. Outbreak of a multiresistant *Klebsiella pneumoniae* strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. *Clin. Infect. Dis.* 30:55–60.
- Aygün G., Demirkiran O., Utku T. 2002. Environmental contamination during a carbapenem-resistant *A. baumannii* outbreak in an intensive care unit. *J Hosp Infect.* 52:259–62.
- Bergogne-Berezin. 2009. Importance of *Acinetobacter* spp. *Acinetobacter* biology and pathogenesis. *Infect. Agents Pathol.* 1–18
- Bisson, G., N. O. Fishman, J. B. Patel, P. H. Edelstein, dan E. Lautenbach. 2002. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella species*: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. *Infect. Control Hosp. Epidemiol.* 23:254–260.
- Bonomo R.A., Szabo D. 2006. *Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa*. *Clin Infect Dis*; 43(Suppl 2):49–56.
- Bouvet, P.J.M., dan M.L. Joly-Guillou. 2000. *Acinetobacter* spp.p. 34–86. In J. Freney, F. Renaud, W. Hansen, dan C. Bollet (ed.), *Summary of Clinical Bacteriology*. Eska, Paris.
- Bush, K., Jacoby, G.A., dan Medeiros, A. A. 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrobial Agents & Chemotherapy*, 39(6), 1211-33.
- Capoor, M.R., D. Nair, L. Srivastava, B. Gupta dan P. Aggarwal, 2005. Characterization and changing Minimum Inhibitory Concentration (MIC) of *Acinetobacter* species from a tertiary care setup. *J. Commun. Dis.*, 37: 99-107. PMID: 16749272
- Chang HC, Chen YC, Lin MC, Liu SF, Chung YH, Su MC, Fang WF, Tseng CC, Lie CH, Huang KT, dan Wang CC. 2011. Mortality risk factors in patients with *Acinetobacter baumannii* ventilator: associated pneumonia. *J Formos Med Assoc*;110:564-571.
- Chastre J. T.J., Vuagnat A., dan Joly-Guillou M.L.1996. Nosocomial pneumonia caused by *Acinetobacter* spp.: *New York: CRC Press*.
- Chuang Y.C., Sheng W.H., Li S.Y., Lin Y.C., Wang J.T., Chen Y.C., dan Chang S.C. 2011. Influence of genospecies of *Acinetobacter baumannii* complex

- on clinical outcomes of patients with acinetobacter bacteremia. *Clin Infect Dis* ;52:352-360.
- Clinical and Laboratory Standard Institute. 2006. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. *CLSI document M100-S16*. CLSI, Wayne, Pa.
- Constantiniu, S., Romaniuc, A., Iancu, Luminița S., Filimon, R., Tarași, I. 2004. Cultural And Biochemical Characteristics of *Acinetobacter Spp*. Strains Isolated From Hospital Units. *The Journal Of Preventive Medicine*. 12 (3-4): 35-42.
- De Champs, C., D. Rouby, D. Guelon, J. Sirot, D. Sirot, D. Beytout, dan J. M. Gourgand. 1991. A case-control study of an outbreak of infections caused by *Klebsiella pneumoniae* strains producing CTX-1 (TEM-3) betalactamase. *J. Hosp. Infect.* 18:5–13.
- De Luca, M., Angelino, G., Carducci, F. I. C., Martino, A., Bernardi, S., Bernaschi, P., Palma, P. 2011. Multidrug-resistant *Acinetobacter baumannii* infection in children. *Case Reports, 2011*
- Denman, S. J., dan J. R. Burton. 1992. Fluid intake and urinary tract infection in the elderly. *JAMA* 267:2245–2249.
- Dijkshoorn L. 2006. Two decades experience of typing *Acinetobacter* strains: evolving methods and clinical applications. *Antibiotiques* 8:108-116.
- Dijkshoorn L., Nemec A., Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 5:939-951.
- Duggal, Shalini , Rajni Gaiind, Neha Tandon, Manorama Deb, dan Tulsi Das Chugh. 2012. Comparison of an Automated System with Conventional Identification and Antimicrobial Susceptibility Testing. *ISRN Microbiology*.
- Fouzia, B., dan As, D. 2015. Medical Microbiology & Diagnosis Prevalence and Characterization of Extended Spectrum Beta-Lactamase Production in Clinical Isolates of *Klebsiella pneumonia*, 4(2), 2–7.
- Garnacho-Montero J., Ortiz-Leyba C., Fernandez-Hinojosa E., Aldabo-Pallas T., Cayuela A., Marquez-Vacaro J.A., Garcia-Curiel A., Jimenez-Jimenez F.J. 2005. *Acinetobacter baumannii* ventilator-associated pneumonia: epidemiological and clinical findings. *Intensive Care Med* 31:649-655.
- Gustawan I.W., Satari H.I, Amir I., Atrawinata D.A.W. 2014. Gambaran Infeksi *Acinetobacter baumannii* dan pola sensitivitasnya terhadap antibiotika. *Sari Pediatri*, 16 (1): 35-40
- Howard A., O'Donoghue M., Feeney A., Sleator R.D. 2012. *Acinetobacter baumannii*: an emerging opportunistic pathogen. *Virulence* 3:243-250.
- Jain, R., and L.H. Danziger. 2004. Multi-drug resistant *Acinetobacter* infections: An emerging challenge to clinicians. *Ann. Pharmacother.* 38:1449–1459.
- James, H., Ndakidemi, P., Susan, I., Benade, S. 2011. The Ecology, Biology and Pathogenesis of *Acinetobacter spp.*: An Overview. *Microbes Environ. Vol.* 26, No. 2, 000–000.
- Joly-Guillou, M.L. 2005. Clinical impact and pathogenicity of *Acinetobacter*. *Eur. Soc. Clin. Microbiol. Infect. Dis.* 11:868–873.

- Joshi SG, Litake GM, Niphadkar KB, Ghole VS. 2003. Multidrug resistant *Acinetobacter baumannii* isolates from teaching hospital. *J Infect Chemother.* 9 (2): 187-90.
- Karageorgopoulos, D.E., Kelesidis, T., Kelesidis, I., Falagas, M.E., 2008. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) *Acinetobacter* infections: a review of the scientific evidence. *J. Antimicrob. Chemother.* 62, 45–55.
- Korbila I.P., Michalopoulos A., Rafailidis P.I., Nikita D., Samonis G., Falagas M.E. 2010. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. *Clin Microbiol Infect* 16:1230-1236.
- Kumar, E. 2013. Prevalence of various β -lactamase (ESBL, AmpC and MBL) producing multidrug resistant clinical isolates of *Acinetobacter* spp. in tertiary care hospital. *Asian Journal of Pharmaceutical and Clinical Research*, Volume 6.
- Kurcik-Trajkovska, B. 2009. *Acinetobacter* spp.—a serious enemy threatening hospitals worldwide. *Macedonian. J. Med. Sci.* 2:157–162
- Lautenbach, E., B. L. Strom, W. B. Bilker, J. B. Patel, P. H. Edelstein, dan N. O. Fishman. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Clin. Infect. Dis.* 33:1288–1294.
- Litake, G. M., Ghole, V. S., Niphadkar, K. B., dan Joshi, S. G. 2015. Phenotypic ESBL detection in *Acinetobacter baumannii*: A real challenge. *Revista Brasileira de Gestao E Desenvolvimento Regional*, 11(3), 48–53.
- Litake, G.M., V.S. Ghole, K.B. Niphadkar dan S.G. Joshi. 2009. PER-1-type extended-spectrum beta-lactamase- producing *Acinetobacter baumannii* clinical isolates from India. *Int. J. Antimicrob Agents*, 34: 388-389.
- Marwoto, Agus, Hari Kusnanto, dan Dwi Handono. 2007. Analisis Kinerja Perawat dalam Pengendalian Infeksi Nosokomial di Ruang IRNA 1 RSUP. Dr. Sardjito. Yogyakarta
- Mahon, Conie R., Lehmanm Donald C., dan Manuselis, George. 2015. Textbook of Diagnostic Microbiology. 5th ed. Missouri: Elsevier.
- Mayon-White R.T., Duce G., Kereselidze T., Tikomirov E. 1988. An international survey of the prevalence of hospital-acquired infection. *J Hosp Infect.*
- Murray P.R., Rosenthal K.S., Pfaller. 2013. Medical Microbiology. 7th ed. Elsevier Saunders.
- Muzslay, M., Moore, G., Alhussaini, N., & Wilson, A. P. R. 2017. ESBL-producing Gram-negative organisms in the healthcare environment as a source of genetic material for resistance in human infections. *Journal of Hospital Infection*, 95(1), 59–64.
- Naas T., Nordmann P. 1999. OXA- type beta-lactamase. *Curr Pharm Des* 5:865-79.

- Naas, T., P. Bogaerts, C. Bauraing, Y. Degheldre dan Y. Glupczynski. 2006. Emergence of PER and VEB extended-spectrum beta-lactamases in *Acinetobacter baumannii* in Belgium. *J. Antimicrob Chemother*, 58: 178-182.
- Nikaido Hiroshi. 2009. Multidrug Resistance in Bacteria. *Annu Rev Biochem*. 78: 119-146
- O'Shea MK. 2012. *Acinetobacter* in modern warfare. *Int J Antimicrob Agents* 39:363-375.
- Pasteran, F., M. Rapoport, A. Petroni, D. Faccone dan A. Corso. 2006. Emergence of PER-2 and VEB-1a in *Acinetobacter baumannii* Strains in the Americas. *Antimicrob Agents Chemother*, 50: 3222-3224.
- Paterson, D. L., dan R. A. Bonomo. 2005. *Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev.* 18:657-686.
- Pena, C., M. Pujol, A. Ricart, C. Ardanuy, J. Ayats, J. Linares, F. Garrigosa, J. Ariza, dan F. Gudiol. 1997. Risk factors for faecal carriage of *Klebsiella pneumoniae* producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. *J. Hosp. Infect.* 35:9-16
- Poirel, L., A. Karim, A. Mercat, I. Le Thomas dan H. Vahaboglu et al., 1999. Extended-spectrum β -lactamase-producing strain of *Acinetobacter baumannii* isolated from a patient in France. *J. Antimicrob Chemother*, 43: 157-158.
- Poirel, L., Gniadkowski, M., dan Nordmann, P. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. *J Antimicrob Chemother*, 50, 1031-1034.
- Ponce-de-Leon S. 1991. The needs of developing countries and the resources required. *Journal of Hospital Infection*. 18 Suppl A:376-381.
- Rice L.B. 2006. Challenges in identifying new antimicrobial agents effective for treating infections with *A. baumannii* and *Pseudomonas aeruginosa*. *Clin Infect Dis* 43 (Suppl 2):100-5.
- Rice, L. B., E. C. Eckstein, J. DeVente, dan D. M. Shlaes. 1996. Ceftazidime-resistant *Klebsiella pneumoniae* isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. *Clin. Infect. Dis.* 23:118-124.
- Ristuccia, Patricia A., Cunha Burke A. 1983. The Society for Healthcare Epidemiology of America, Cambridge University Press. *Infection Control and Hospital Epidemiology*, 21(6), 394-397.
- Ryan K.J dan Ray C.G (editors). 2014. Sherris Medical Microbiology. McGraw-Hill Education. 6th Ed.
- Safari, M., Mozaffari Nejad, A. S., Bahador, A., Jafari, R., dan Alikhani, M. Y. 2015. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi Journal of Biological Sciences*, 22(4), 424-429.
- Scott P., Deye G., Srinivasan A., Murray C., Moran K., Hulten E., Fishbain J., Craft D., Riddell S., Lindler L., Mancuso J., Milstrey E., Bautista C.T., Patel J., Ewell A., Hamilton T., Gaddy C., Tenney M., Christopher G.,

- Petersen K., Endy T., Petrucci B. 2007. An outbreak of multidrug-resistant *Acinetobacter baumannii-calcoaceticus* complex infection in the US military health care system associated with military operations in Iraq. *Clin Infect Dis* ;44:1577-84.
- Sebeny P.J., Riddle M.S., Petersen K. 2008. *Acinetobacter baumannii* skin and soft-tissue infection associated with war trauma. *Clin Infect Dis* 2008;47:444-9.
- Siegel J.D., Rhinehart E., Jackson M., Chiarello L. 2006. Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings. *Atlanta: Centers for Disease Control and Prevention*.
- Suwarni, A., 2001. *Infeksi Nosokomial*. Yogyakarta, Badan Litbang Kesehatan Departemen Kesehatan dan Kesejahteraan.
- Tena D., Martínez N.M., Oteo J. 2013. Outbreak of multiresistant OXA-24-and OXA-51-producing *A. baumannii* in an internal medicine ward. *Jpn J Infect Dis*. 66:323–6.
- Thomson, K. S. 2001. Controversies about extended-spectrum and AmpC beta-lactamases. *Emerg. Infect. Dis*. 7:333–336
- Thomson J.M., Bonomo R.A. 2005. The threat of antibiotic resistance in gram-negative pathogenic bacteria: beta-lactams in peril! *Curr Opin Microbiol* 8:518–24.
- Tripathi, P., & Gajbhiye, S. 2013. Prevalence of Multidrug Resistance , ESBL and MBL production in *Acinetobacter spp* ., 6(3), 139–143.
- Turner, Philip J. 2005. Introduction : Global Antimicrobial Resistance Alerts and Implications Alerts and Implications : The 2005 Report of the Global Advisory on Antibiotic Resistance Global Antimicrobial Resistance Alerts and I, 41(May), 24–26.
- Vahaboglu, H., F. Coskuncan, O. Tansel, R. Ozturk dan N. Sahin. 2001. Clinical importance of extended-spectrum beta-lactamase (PER-1-type)- producing *Acinetobacter spp.* and *Pseudomonas aeruginosa* strains. *J. Med. Microbiol.*, 50: 642-645.
- Wiegand, I., H. K. Geiss, D. Mack, E. Sturenburg, dan H. Seifert. 2007. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. *J. Clin. Microbiol*. 45:1167–1174.
- Wilks M., Wilson A., Warwick S. 2006. Control of an outbreak of multidrug-resistant *A. baumannii* —*calcoaceticus* colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. *Infect Control Hosp Epidemiol* 27:654–8.
- Yong, D., J.H. Shin, S. Kim, Y. Lim dan J.H. Yum et al., 2003. High prevalence of PER-1 extended-spectrum beta-lactamase-producing *Acinetobacter spp.* in Korea. *Antimicrob Agents Chemother*, 47: 1749-1751.
- Zeana C., Larson E., Sahni J., Bayuga S.J., Wu F., Della-Latta P. 2003. The epidemiology of multidrug-resistant *Acinetobacter baumannii*: does the community represent a reservoir? *Infect Control Hosp Epidemiol*. 24:275–9.